DES-Testbed, Freie Universität Research Pig [Assessment of COVID-19 Risky Contact of Healthcare Workers in an University Hospital]

[Assessment of COVID-19 Risky Contact of Healthcare Workers in an University Hospital]


[Assessment of COVID-19 Risky Contact of Healthcare Workers in an University Hospital]

Healthcare staff are the group with the very best threat of COVID-19 transmission. The sickness of healthcare staff poses a threat to sufferers admitted to the hospital, colleagues and households in addition to their very own well being. On this examine, it was aimed to find out the chance evaluation and the elements related to threat standing of an college hospital healthcare staff after dangerous COVID-19 contact. The info of the descriptive examine have been obtained from 773 follow-up information of 555 healthcare staff who utilized with COVID-19 dangerous contact between 06.04-10.05.2020. With the bodily enchancment of the remaining areas of the staff and the association of the breaks, the dangerous contact between colleagues within the social areas shall be lowered.

Workers who have been optimistic for RT-PCR evaluated as “sufferers” and others as “dangerous contact”. Danger evaluation was labeled as no threat, low, medium and excessive threat contact in keeping with the “Algorithm of Evaluation of Well being Employees with COVID-19 Contact” of the Ministry of Well being. The connection between the chance ranges of the individuals and their demographic and office traits and their utilization of non-public safety have been evaluated. Imply, normal deviation, share, chi-square and ANOVA checks have been used within the evaluation of the information. The common age of the healthcare staff was decided as 34.4 ± 7.6 years. It was decided that 56.2% of those that had contact have been feminine, 62.9% have been married and 17.5% had a further illness.

It was decided that 45.6% of the dangerous contacts have been nurses, 18.4% have been supportive personnel and 16.9% have been medical doctors. Whereas 46.5% of the contacts have been discovered as medium, 28.0% low, 17.1% excessive threat and eight.4% threat free. 38.2% of dangerous contacts occurred whereas working in inner/surgical clinics. Whereas 66.0% of the staff had dangerous contact throughout affected person care and therapy, 25% had dangerous contact with colleagues in social settings. Excessive-risk contact was larger in social relations between workers. The supply of the contact was a colleague in 73.2% of the staff.

The common age of high-risk workers was smaller than these of low-risk. Whereas 54.5% of the staff wore surgical masks throughout contact, 67.8% of the sufferers didn’t have a masks. Of 555 workers adopted, 37 (6.7%) have been recognized as COVID-19; 48.6% of the sufferers have been nurses and 18.9% have been medical doctors. It was decided that 48.6% of the healthcare staff have been working within the COVID-19 service, outpatient clinic or intensive care unit on the time of analysis. The supply of the an infection was regarded as a colleague in 51.6% of the sufferers. COVID-19 was extra widespread in nurses and medical doctors.

It was decided that dangerous contact additionally occurred in companies apart from the models the place COVID-19 sufferers have been handled and dangerous contact usually passed off whereas offering healthcare to the sufferers and through social relations between the staff. Unprotected contact of the staff with one another within the office was recognized as an essential threat supply. Insufficient use of non-public protecting tools by healthcare staff led to a rise in medium and excessive threat contacts. The usage of masks by sufferers and their family members in the course of the well being service supply and the correct use of non-public protecting tools by healthcare professionals will scale back the chance.

Challenges for bronchial asthma models in response to COVID-19: a qualitative group dynamics evaluation

To develop a set of suggestions for the administration of extreme bronchial asthma throughout COVID-19 pandemic. Eleven pneumologists and allergologists who have been employees members of formally accredited bronchial asthma models in Catalonia (Spain) participated in a cross-section examine primarily based on three 2-hour digital workshops (first: brainstorming, second: identification of impacts and challenges summarized in 10 matters, third: institution of ultimate suggestions by consensus).

Impacts and challenges recognized have been enchancment of referral protocols between completely different ranges of care; evaluation of the minimal variety of perform checks to be carried out and promote the efficiency of spirometry in major care; implementation of videoconferencing, cellular apps, phone calls, or integral digital platforms for the follow-up of sufferers, and definition of the mannequin of care (face-to-face, telematics, combined) in keeping with the affected person’s particular person wants; self-administration of biologics for domiciliary therapy; and empowerment of the position of nursing and hospital pharmacy specifically for follow-up and self-administration of biologics.

13 mm Diameter Solid Titanium Tip

0-120-0011 13 mm
EUR 533

19 mm Diameter Tapped Titanium Tip

0-120-0012 19 mm
EUR 639

19 mm Diameter Solid Titanium Tip

0-120-0013 19 mm
EUR 570

25 mm Diameter Tapped Titanium Tip

0-120-0014 25 mm
EUR 682

25 mm Diameter Solid Titanium Tip

0-120-0015 25 mm
EUR 614

Flat Replaceable Tips 13 mm Diameter Flat Titanium Tip

0-120-0016 13 mm
EUR 86
Description: use with corresponding Tapped Tips and Tapped Extender Tips

Flat Replaceable Tips 19 mm Diameter Flat Titanium Tip

0-120-0017 19 mm
EUR 92
Description: use with corresponding Tapped Tips and Tapped Extender Tips

Flat Replaceable Tips 25 mm Diameter Flat Titanium Tip

0-120-0018 25 mm
EUR 100
Description: use with corresponding Tapped Tips and Tapped Extender Tips

Titanium Cup Tip, 250 ml

0-120-0019 250 ml
EUR 1377
Description: includes Interface Washers

Microtube Tray, 8 Position (for 250 ml Cup Tip)

0-120-0021 each
EUR 113
Description: includes Interface Washers

Continuous Flow Chamber

0-120-0026 each
EUR 774
Description: includes Interface Washers

Interface Washers 1.5” Diameter, 5/Pkg

0-120-003 1.5'' Diameter
EUR 31

13 mm Diameter Solid Titanium Extender Tip

0-120-0032 13 mm
EUR 301

13 mm Diameter Tapped Titanium Extender Tip

0-120-0033 13 mm
EUR 362

19 mm Diameter Solid Titanium Extender Tip

0-120-0034 19 mm
EUR 315

19 mm Diameter Tapped Titanium Extender Tip

0-120-0035 19 mm
EUR 375

25 mm Diameter Solid Titanium Extender Tip

0-120-0036 25 mm
EUR 328

25 mm Diameter Tapped Titanium Extender Tip

0-120-0037 25 mm
EUR 389

KoldPod, 1.5ml Micro Tube

0-120-0038 1.5 ml
EUR 152
Description: Thermo conductive tube pods

KoldPod, 15ml Conical Tube

0-120-0039 15 ml
EUR 275
Description: Thermo conductive tube pods

KoldPod, 50ml Conical Tube

0-120-0040 50 ml
EUR 290
Description: Thermo conductive tube pods

Model 150 V/T Ultrasonic Homogenizer

0-121-0002 210-240V/50-60Hz
EUR 2920
Description: Delivers up to 150 Watts of ultrasonic power to the Titanium Tip. The Timer and Duty Cycle function increase preciosion in sample processing processing.

Model 300 V/T Ultrasonic Homogenizer

0-122-0002 210-240V/50-60Hz
EUR 3520
Description: Delivers up to 300 Watts of ultrasonic power to the Titanium Tip. The Timer and Duty Cycle function increase preciosion in sample.

SONABOZ Sound Abating Chamber

0-125-0001 each
EUR 1020
Description: Reduces cavitational sound emitted during processing.

Model 3000 Ultrasonic Homogenizer

0-127-0002 210-240V/50-60Hz
EUR 4120
Description: Delivers up to 300 Watts of ultrasonic power to the Titanium Tip and includes an intergrated Sound Abating Chmaber to reduce cavitational sound emitted during processing. The Timer and Duty Cycle function increase preciosion in sample.

Model 3000MP Ultrasonic Homogenizer

0-128-0002 210-240V/50-60Hz
EUR 4720
Description: Delivers up to 300 Watts of ultrasonic power to the Titanium Tip with preciosion control from a microprocessor and a graphical user interface displayed on a large (145 mm) LCD display. The integrated Sound Abating Chamber reduces cavitational sound emitted during processing.

OMNICON® Zone Reader, 210-240V/50-60Hz

0-131-0002 210-240V/50-60Hz
EUR 35200
Description: Designed to Perform multi-plate Assays on round 90/100mm Petri Dishes. The integrated LED illumination system provides transmitted light for brightfield and darkfield illumination of transparent media.

OMNI-Noculator Peni Cylinder Filler, 210-240V/50-60Hz

0-134-0002 210-240V/50-60Hz
EUR 32200
Description: A robotic liquid handling system designed to dispense Peni Cylinders and fill Peni Cylinders with the corresponding antibiotic liquid sample.

Peni Cylinder Dispenser with Manual Hopper

0-144-0002 each
EUR 5406
Description: Dispenser can be configured to dispense 4 or 6 Peni Cylinders onto a petri dish.

Peni Cylinder Dispenser with Motorized Hopper, 100-240V/50-60Hz

0-144-0003 100-240V/50-60Hz
EUR 6254
Description: The motorized hopper can be configured to dispense 4 or 6 Peni Cylinders onto a petri Dispenser can be disassembled for disinfection.

Stainless Steel Peni Cylinder with Flat Face

0-144-0005 6mm I.D. x 8mm O.D. x 10mm Long
EUR 399
Description: sold in packages of 100 pieces

Stainless Steel Peni Cylinder with Chamfered Face

0-144-0006 6mm I.D. x 8mm O.D. x 10mm Long
EUR 412
Description: sold in packages of 100 pieces

Custom development of ELISAs for other species or antibody isotypes not listed in the catalog. Custom testing of samples for IgG/IgM/IgA or total (IgG+IgM+IgA)

000-CUS Custom
EUR 602

Alpha-Bungarotoxin, CF®405S, 500 ug

00002 1UG
EUR 527
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus)

Alpha-bungarotoxin, CF405s

00002 500uG
EUR 594
Description: Minimum order quantity: 1 unit of 500uG

Alpha-Bungarotoxin, CF®405S, 500 ug

00002-1 EA
EUR 527

Alpha-Bungarotoxin, CF®405S 100ug

00002-100ug 100uG
EUR 132
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus)

Alpha-Bungarotoxin, CF®680R, 500 ug

9-00003
  • Ask for price
  • Ask for price
  • 500uG
  • 100uG
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus)

Alpha-Bungarotoxin, CF®680R, 500 ug

00003-1 EA
EUR 527

Alpha-Bungarotoxin, CF®680R 100ug

9-00003
  • Ask for price
  • Ask for price
  • 500uG
  • 100uG
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus)

Alpha-Bungarotoxin, CF®640R, 500 ug

9-00004
  • Ask for price
  • Ask for price
  • 500uG
  • 100uG
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus)

Alpha-Bungarotoxin, CF®640R, 500 ug

00004-1 EA
EUR 527

Alpha-Bungarotoxin, CF®640R 100ug

9-00004
  • Ask for price
  • Ask for price
  • 500uG
  • 100uG
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus)

Alpha-Bungarotoxin, CF®488A, 500 ug

9-00005
  • Ask for price
  • Ask for price
  • 500uG
  • 100uG
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus)

Alpha-Bungarotoxin, CF®488A, 500 ug

00005-1 EA
EUR 527

Alpha-Bungarotoxin CF®488A 100ug

9-00005
  • Ask for price
  • Ask for price
  • 500uG
  • 100uG
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus)

Alpha-Bungarotoxin, CF®568, 500 ug

9-00006
  • Ask for price
  • Ask for price
  • 500uG
  • 100uG
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus)

Alpha-Bungarotoxin, CF®568, 500 ug

00006-1 EA
EUR 527

Alpha-Bungarotoxin, CF®568 100ug

9-00006
  • Ask for price
  • Ask for price
  • 500uG
  • 100uG
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus)

Alpha-Bungarotoxin, CF®594, 500 ug

9-00007
  • Ask for price
  • Ask for price
  • 500uG
  • 100uG
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus)

Alpha-Bungarotoxin, CF®594, 500 ug

00007-1 EA
EUR 527

Alpha-Bungarotoxin CF®594 100ug

9-00007
  • Ask for price
  • Ask for price
  • 500uG
  • 100uG
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus)

Alpha-Bungarotoxin, CF®633, 500 ug

9-00009
  • Ask for price
  • Ask for price
  • 500uG
  • 100uG
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus)

Alpha-Bungarotoxin, CF®633, 500 ug

00009-1 EA
EUR 527

Alpha-Bungarotoxin, CF®633 100ug

9-00009
  • Ask for price
  • Ask for price
  • 500uG
  • 100uG
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus)

SARS-CoV-2 Indicator Cell Line for RNA Replication - GFP Reporter only

0001-PP-001 1 cell line (can order x amount)
EUR 12000
Description: SARS-CoV-2 GFP reporter cell line using HEK293T (ACE2/TMPRSS2) cells

Alpha-Bungarotoxin, 1 mg

00010-1 1MG
EUR 193
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus)

Alpha-Bungarotoxin, 1 mg

00010-1-1 EA
EUR 193

Fluorescein-Alpha-Bungarotoxin, 500 ug

00011 500uG
EUR 376
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus)

Fluorescein-Alpha-Bungarotoxin, 500 ug

00011-1 EA
EUR 376

Tetramethylrhodamine-Alpha-Bungarotoxin, 500 ug

00012 500uG
EUR 394
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus)

Tetramethylrhodamine-Alpha-Bungarotoxin, 500 ug

00012-1 EA
EUR 394

Fluorescein-alpha-bungarotoxin, 10x50ug

00013 10ST
EUR 436
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus)

Fluorescein-alpha-bungarotoxin, 10x50ug

00013-1 EA
EUR 436

Tetramethylrhodamine-A-Bungarotoxin, 10x50 ug

00014 10ST
EUR 494
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus)

Tetramethylrhodamine-A-Bungarotoxin, 10x50 ug

00014-1 EA
EUR 494

Sulforhodamine 101-Alpha-Bungarotoxin, 500 ug

00015 500uG
EUR 494
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus)

Sulforhodamine 101-Alpha-Bungarotoxin, 500 ug

00015-1 EA
EUR 494

Sulforhodamine 101-Alpha-Bungarotoxin, 50 ug

00016 10ST
EUR 560
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus)

Sulforhodamine 101-Alpha-Bungarotoxin, 50 ug

00016-1 EA
EUR 560

Biotin-XX-A-Bungarotoxin, 500 ug

00017 500uG
EUR 455
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus)

Biotin-XX-A-Bungarotoxin, 500 ug

00017-1 EA
EUR 455

Alpha-Bungarotoxin, CF®555, 500 ug

9-00018
  • Ask for price
  • Ask for price
  • 500uG
  • 100ug
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus)

Alpha-Bungarotoxin, CF®555, 500 ug

00018-1 EA
EUR 527

Alpha-Bungarotoxin, CF®555 100ug

9-00018
  • Ask for price
  • Ask for price
  • 500uG
  • 100ug
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus)

Acrylamide, Chemzymes Ultra Pure®

00019-100 100g
EUR 101.52
Description: 79-06-1

Acrylamide, Chemzymes Ultra Pure®

00019-500 500g
EUR 270
Description: 79-06-1

Biotin-cAMP, 1 mg

00020 1MG
EUR 298
Description: N/A

Biotin-cAMP, 1 mg

00020-1 20ST
EUR 298
Description: N/A

Biotin-cAMP, 50 ug

00020-1-1 EA
EUR 414

Biotin-cGMP, 1 mg

00021 1MG
EUR 331
Description: N/A

Biotin-cGMP, 1 mg

00021-1 20ST
EUR 331
Description: N/A

Biotin-cGMP, 20x50 ug

00021-1-1 EA
EUR 447

Cyanine 644-cAMP, 1 mg

00022 1MG
EUR 496
Description: N/A

Cyanine 644-cAMP, 1 mg

00022-1 20ST
EUR 496
Description: N/A

Cyanine 644-cAMP, 20x50 ug

00022-1-1 EA
EUR 647

Fluorescein Methotrexate, Triammonium Salt, 1 mg

00023 1MG
EUR 285
Description: N/A

Fluorescein Methotrexate, Triammonium Salt, 1 mg

00023-1 EA
EUR 285

Staurosporine

00025 100uG
EUR 100
Description: N/A

Staurosporine

00025-1 EA
EUR 100

Alpha-Bungarotoxin, CF®543, 500 ug

00026 500uG
EUR 527
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus)

Alpha-Bungarotoxin, CF®543, 500 ug

00026-1 EA
EUR 527

Alpha-Bungarotoxin, CF®543, 100 ug

00026-100ug 1UG
EUR 132
Description: Alpha-bungarotoxin from Krait snake venom (Bungarus multicinctus)

Rhodamine Phalloidin 300U

00027 300
EUR 364
Description: N/A

Rhodamine Phalloidin 300U

00027-1 EA
EUR 364

Biotin-XX-Phalloidin

00028 100U
EUR 466
Description: N/A

Biotin-XX-Phalloidin

00028-1 EA
EUR 466

Fluorescein-Phalloidin

00030 300U
EUR 364
Description: N/A

Fluorescein-Phalloidin

00030-1 EA
EUR 364

Rhodamine 110 Phalloidin

00032 300ST
EUR 364
Description: N/A

Rhodamine 110 Phalloidin

00032-1 EA
EUR 364

Sulforhodamine 101 (Texas Red®) Phalloidin

00033 300EU
EUR 364
Description: N/A

Sulforhodamine 101 (Texas Red®) Phalloidin

00033-1 EA
EUR 364

Phalloidin, CF®405M

00034 300U
EUR 482
Description: N/A

Phalloidin, CF®405M

00034-1 EA
EUR 482

Phalloidin, CF®405M

00034-T 50U
EUR 101
Description: N/A

Phalloidin, CF®405M

00034-T-1 EA
EUR 101

CF®488A-cAMP

00036 100ug
EUR 136
Description: N/A

CF®488A-cAMP

00036-1 EA
EUR 136

CF®640R-cAMP

00037 100ug
EUR 136
Description: N/A

CF®640R-cAMP

00037-1 EA
EUR 136

Phalloidin, CF555

00040 300U
EUR 530.4
Description: Minimum order quantity: 1 unit of 300U

Phalloidin, CF555

00040-T 50U
EUR 159.6
Description: Minimum order quantity: 1 unit of 50U

Phalloidin, CF®647, 300 U

00041 300U
EUR 482
Description: N/A

Phalloidin, CF®647, 300 U

00041-1 EA
EUR 482

Phalloidin, CF®647, 50 U

00041-T 50U
EUR 101
Description: N/A

Phalloidin, CF®647, 50 U

00041-T-1 EA
EUR 101

Phalloidin, CF®488A, 300 U

00042 300U
EUR 482
Description: N/A

Phalloidin, CF®488A, 300 U

00042-1 EA
EUR 482

Phalloidin, CF®488A, 50 U

00042-T 50U
EUR 101
Description: N/A

Phalloidin, CF®488A, 50 U

00042-T-1 EA
EUR 101

Phalloidin, CF®543, 300 U

00043 300U
EUR 482
Description: N/A

Phalloidin, CF®543, 300 U

00043-1 EA
EUR 482

Phalloidin, CF®543, 50 U

00043-T 50U
EUR 101
Description: N/A

Phalloidin, CF®543, 50 U

00043-T-1 EA
EUR 101

Phalloidin, CF®568, 300 U

00044 300U
EUR 482
Description: N/A

Phalloidin, CF®568, 300 U

00044-1 EA
EUR 482

Phalloidin, CF®568, 50 U

00044-T 50U
EUR 101
Description: N/A

Phalloidin, CF®568, 50 U

00044-T-1 EA
EUR 101

Phalloidin, CF®594, 300 U

00045 300U
EUR 482
Description: N/A

Phalloidin, CF®594, 300 U

00045-1 EA
EUR 482

Phalloidin, CF®594, 50 U

00045-T 50U
EUR 101
Description: N/A

Phalloidin, CF®594, 50 U

00045-T-1 EA
EUR 101

Phalloidin, CF®633, 300 U

00046 300U
EUR 482
Description: N/A

Phalloidin, CF®633, 300 U

00046-1 EA
EUR 482

Phalloidin, CF®633, 50 U

00046-T 50U
EUR 101
Description: N/A

Phalloidin, CF®633, 50 U

00046-T-1 EA
EUR 101

Phalloidin, CF®660R, 300 U

00047 300U
EUR 482
Description: N/A

Phalloidin, CF®660R, 300 U

00047-1 EA
EUR 482

Phalloidin, CF®660R, 50 U

00047-T 50U
EUR 101
Description: N/A

Phalloidin, CF®660R, 50 U

00047-T-1 EA
EUR 101

Phalloidin, CF®680R, 300 U

00048 300U
EUR 513
Description: N/A

The primary suggestions included coordination between major care and specialised care session, optimization of lung perform testing, implementation of telemedicine, and the position of nursing and hospital pharmacy. The precise proposals in response to the impact of COVID-19 pandemic centered on 4 areas of curiosity (coordination between major care and specialised care, optimization of lung perform testing, implementation of telemedicine, and empowerment of the position of nursing and hospital pharmacy) could also be generalized to different well being care settings, and assist to introduce new methods of caring bronchial asthma sufferers within the COVID-19 context.

[Assessment of COVID-19 Risky Contact of Healthcare Workers in an University Hospital]

Neighborhood-led HIV self-testing for males who’ve intercourse with males in Lebanon: classes discovered and influence of COVID-19

The NAP performed a collection of workshops (July-November 2018) to introduce HIVST companies for healthcare staff working at completely different NGOs. The workshops highlighted that HIVST could be distributed free of charge, that it will be confidential and voluntary, and that individuals have been inspired to inform the NGOs of their outcomes, which might be saved strictly confidential. NGOs collected knowledge anonymously and confidentially from beneficiaries (age, consistency of condom use and HIV testing historical past), who have been requested to name again with the outcomes of their HIVST. On the NAP, knowledge have been mixed, aggregated and analysed.

Leave a Reply

Your email address will not be published. Required fields are marked *